Drug Development for Metastasis Prevention.
Drug Development for Metastasis Prevention.
复制标题
预防转移的药物开发。
DOI：
10.1615/critrevoncog.v20.i5-6.150
复制
发表时间：
2015
影响因子：
--
通讯作者：
Dubinett SM
中科院分区：
文献类型：
--
作者：
Fontebasso Y;Dubinett SM
转移性疾病导致90%的实体瘤死亡。然而，只有少数转移特异性靶点在治疗上得到了利用，有效预防和抑制转移性疾病仍然是一个难以实现的目标。在这篇综述中，我们将首先总结目前的知识状态的分子特征的疾病，特别关注的步骤和目标可能服从治疗干预。然后，我们将讨论目前肿瘤治疗药物库中转移性药物缺乏的原因，以及克服这种治疗差距的潜在方法。我们的理由是，发现新的有希望的目标，增加对疾病的分子特征的理解，破坏性技术的影响以及当前临床前和临床环境的转变有可能创造更成功的药物开发努力。
Metastatic disease is responsible for 90% of death from solid tumors. However, only a minority of metastasis-specific targets has been exploited therapeutically, and effective prevention and suppression of metastatic disease is still an elusive goal. In this review, we will first summarize the current state of knowledge about the molecular features of disease, with particular focus on steps and targets potentially amenable to therapeutic intervention. We will then discuss the reasons underlying the paucity of metastatic drugs in the current oncological arsenal and potential ways to overcome this therapeutic gap. We reason that the discovery of novel promising targets, an increased understanding of the molecular features of the disease, the effect of disruptive technologies and a shift in the current pre-clinical and clinical settings have the potential to create more successful drug development endeavors.